Comparative Pharmacology
Head-to-head clinical analysis: NEPHROSCAN versus RADIOGENIX SYSTEM.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NEPHROSCAN versus RADIOGENIX SYSTEM.
NEPHROSCAN vs RADIOGENIX SYSTEM
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Calcium trisodium pentetate (NEPHROSCAN) chelates gadolinium ions by forming a stable complex with the metal, thereby reducing the toxicity and enhancing elimination of gadolinium from the body. It acts as a decorporation agent for gadolinium.
RADIOGENIX SYSTEM is a radiopharmaceutical that emits beta radiation (yttrium-90 microspheres) to deliver targeted radiotherapy to hepatic tumors via intra-arterial administration, causing irreversible DNA damage and cell death.
1 to 5 mCi (37 to 185 MBq) as a single intravenous injection for renal imaging.
Not applicable; the RADIOGENIX SYSTEM is a medical imaging device, not a pharmacologic agent. No standard dosing.
None Documented
None Documented
Terminal elimination half-life: 1.6 hours in normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Physical half-life of 6.0 hours for Tc-99m; effective half-life is approximately 6.0 hours due to rapid renal clearance.
Renal: 95% as unchanged drug via glomerular filtration; no biliary/fecal excretion.
Primarily renal excretion; >95% of administered activity excreted in urine within 24 hours; negligible biliary or fecal elimination.
Category C
Category C
Diagnostic Radiopharmaceutical
Diagnostic Radiopharmaceutical